Compare STIM & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | RCEL |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.5M | 126.8M |
| IPO Year | 2018 | N/A |
| Metric | STIM | RCEL |
|---|---|---|
| Price | $2.05 | $5.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $3.00 | ★ $7.88 |
| AVG Volume (30 Days) | ★ 1.4M | 358.7K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $52,776,000.00 | N/A |
| Revenue This Year | $11.10 | $17.17 |
| Revenue Next Year | $11.92 | $49.82 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $3.22 |
| 52 Week High | $4.84 | $7.12 |
| Indicator | STIM | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 69.59 | 64.56 |
| Support Level | $1.21 | $3.55 |
| Resistance Level | $2.19 | $5.32 |
| Average True Range (ATR) | 0.22 | 0.45 |
| MACD | 0.04 | 0.08 |
| Stochastic Oscillator | 71.90 | 73.53 |
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.